Jin-Young Yoon
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Jin-Young Yoon has a total of 145 co-authors. Here are the top co-authors by number of shared publications:
- Barry London
Division of Cardiovascular Medicine, University of Iowa, Iowa City, Iowa, USA
9 shared publications - Kaikobad Irani
Division of Cardiovascular Medicine, University of Iowa Carver College of Medicine, Iowa City, USA
6 shared publications Hana Cho
Department of Physiology, Sungkyunkwan University School of Medicine, Suwon, Korea
4 shared publications- Ryan L. Boudreau
Abboud Cardiovascular Research Center, Division of Cardiovascular Medicine, Department of Internal Medicine, Carver College of Medicine, University of Iowa
4 shared publications - Ajit Vikram
Division of Cardiovascular Medicine, University of Iowa Carver College of Medicine, Iowa City, USA
3 shared publications Haider Mehdi
Division of Cardiovascular Medicine, Department of Internal Medicine, University of Iowa, Iowa City, Iowa; Abboud Cardiovascular Research Center, University of Iowa Carver College of Medicine, Iowa City, Iowa
3 shared publications
Latest Publications
- 24 April 2026
- Published by Wolters Kluwer Health in Circulation Research
- Vol. 138 (9)
Sodium Channel Isoform Diversity Underlies Chamber-Specific Cardiac Excitability
BACKGROUND: Na V (voltage-gated sodium) channels drive cardiac excitability. Although Na V 1.5 is the primary cardiac isoform, the composition and functional contributions of non-Na V 1.5 isoforms in the heart remain unclear. METHODS: Here, we developed a chemical-genetic mouse model (Na V 1.5 GX/GX ) in which Na V 1.5 can be selectively and reversibly inhibited by acyl- and aryl-sulfonamide compounds (GX [acyl- and aryl-sulfonamide compounds typically denoted by the name GX-### and associated items] drugs). Cardiac activity was assessed by electrocardiograms in vivo, and optical mapping was used for imaging of ex vivo hearts. Whole-cell voltage-clamp in tandem with validated toxins and isoform-selective inhibitors were used to examine sodium current composition. RESULTS: Na V 1.5 GX/GX mice exhibited normal cardiac function at baseline, but acute GX drug administration caused profound conduction defects and arrhythmias. Whole-heart optical mapping revealed dose-dependent chamber-specific sensitivity to Na V 1.5 inhibition, with the right ventricle being the most sensitive, followed by the left ventricle, left atrium, and right atrium. Patch-clamp recordings of isolated cardiomyocytes with application of Na V isoform-selective inhibitors showed that Na V 1.5 contributed 93% of sodium current in the left ventricle, 79% in the right ventricle, and 78% in the atria. Non-Na V 1.5 isoforms were differentially enriched across chambers: Na V 1.8 in the left ventricle, Na V 1.1/1.3 in the right ventricle, and Na V 1.2/1.6/1.7 in the atria. CONCLUSIONS: These results reveal a surprising chamber-specific isoform landscape of cardiac sodium currents, which may underlie the right ventricular predominant phenotype of Brugada syndrome. These data highlight non-Na V 1.5 isoforms as potential mediators of chamber-specific cardiac pathologies and as pharmacological targets.
- 24 April 2026
- Published by Wolters Kluwer Health in Circulation Research
- Vol. 138 (9)
Sodium Channel Isoform Diversity Underlies Chamber-Specific Cardiac Excitability
BACKGROUND: Na V (voltage-gated sodium) channels drive cardiac excitability. Although Na V 1.5 is the primary cardiac isoform, the composition and functional contributions of non-Na V 1.5 isoforms in the heart remain unclear. METHODS: Here, we developed a chemical-genetic mouse model (Na V 1.5 GX/GX ) in which Na V 1.5 can be selectively and reversibly inhibited by acyl- and aryl-sulfonamide compounds (GX [acyl- and aryl-sulfonamide compounds typically denoted by the name GX-### and associated items] drugs). Cardiac activity was assessed by electrocardiograms in vivo, and optical mapping was used for imaging of ex vivo hearts. Whole-cell voltage-clamp in tandem with validated toxins and isoform-selective inhibitors were used to examine sodium current composition. RESULTS: Na V 1.5 GX/GX mice exhibited normal cardiac function at baseline, but acute GX drug administration caused profound conduction defects and arrhythmias. Whole-heart optical mapping revealed dose-dependent chamber-specific sensitivity to Na V 1.5 inhibition, with the right ventricle being the most sensitive, followed by the left ventricle, left atrium, and right atrium. Patch-clamp recordings of isolated cardiomyocytes with application of Na V isoform-selective inhibitors showed that Na V 1.5 contributed 93% of sodium current in the left ventricle, 79% in the right ventricle, and 78% in the atria. Non-Na V 1.5 isoforms were differentially enriched across chambers: Na V 1.8 in the left ventricle, Na V 1.1/1.3 in the right ventricle, and Na V 1.2/1.6/1.7 in the atria. CONCLUSIONS: These results reveal a surprising chamber-specific isoform landscape of cardiac sodium currents, which may underlie the right ventricular predominant phenotype of Brugada syndrome. These data highlight non-Na V 1.5 isoforms as potential mediators of chamber-specific cardiac pathologies and as pharmacological targets.
- 24 April 2026
- Published by Wolters Kluwer Health in Circulation Research
- Vol. 138 (9)
Short SCN5A Transcript Yields a NaV1.5 Fragment Influencing Cardiac Metabolism
BACKGROUND: SCN5A encodes the cardiac NaV1.5 (voltage-gated Na + channel), classically known for initiating action potentials and recently implicated in cardiomyocyte metabolism via mitochondrial Na + /Ca 2+ exchange. SCN5A variants are linked to arrhythmias and heart failure, but mechanisms controlling SCN5A /NaV1.5 expression and its metabolic interface remain understudied. METHODS: We used bioinformatic approaches to identify novel SCN5A regulatory features and discovered an alternative polyadenylation (APA) signal downstream of exon 2, which is conserved in humans and several other species but not mice. To test its function, we generated knock-in mice harboring the human APA signal. Western blotting, cell fractionation, and fluorescence microscopy were used to characterize the resulting truncated protein isoform that localizes to mitochondria. Mitochondrial functions and metabolites were assessed in neonatal rat cardiomyocytes, human-induced pluripotent stem cell–derived cardiomyocytes, and mouse hearts overexpressing the novel isoform. RESULTS: We identified a well-conserved APA signal downstream of SCN5A exon 2, yielding a truncated transcript isoform ( SCN5A -short). Reanalysis of cardiac APA-seq and mRNA-seq data reveals reduced SCN5A -short expression in failing human hearts. Knock-in of the human APA signal into mice enables expression of SCN5A -short while decreasing full-length SCN5A mRNA. SCN5A -short encodes a novel NaV1.5-NT (N-terminal fragment of NaV1.5) that localizes to the mitochondrial matrix in cardiomyocytes and mouse hearts. Exogenous expression of NaV1.5-NT in cultured cardiomyocytes enhances mitochondrial respiration, ATP production, and mitochondrial reactive oxygen species while depleting NADH (reduced nicotinamide adenine dinucleotide). Native polyacrylamide gel electrophoresis analyses indicate that this coincides with enhanced CI (complex I) activities, as well as context-dependent alterations of CV (complex V) assembly. Moreover, moderate cardiomyocyte-targeted NaV1.5-NT expression in mice was sufficient to rewire the cardiac metabolome, with suggestive evidence of increased fatty acid oxidation. CONCLUSIONS: APA-mediated regulation of SCN5A produces a short transcript encoding NaV1.5-NT, a novel mitochondrial-targeted peptide that supports cardiomyocyte metabolism. While the precise molecular mechanisms remain unresolved, these findings highlight an unforeseen alternative pathway for expanding SCN5A -mitochondrial crosstalk, with potential implications for metabolic changes in heart failure and arrhythmias.
- 24 April 2026
- Published by Wolters Kluwer Health in Circulation Research
- Vol. 138 (9)
Short SCN5A Transcript Yields a NaV1.5 Fragment Influencing Cardiac Metabolism
BACKGROUND: SCN5A encodes the cardiac NaV1.5 (voltage-gated Na + channel), classically known for initiating action potentials and recently implicated in cardiomyocyte metabolism via mitochondrial Na + /Ca 2+ exchange. SCN5A variants are linked to arrhythmias and heart failure, but mechanisms controlling SCN5A /NaV1.5 expression and its metabolic interface remain understudied. METHODS: We used bioinformatic approaches to identify novel SCN5A regulatory features and discovered an alternative polyadenylation (APA) signal downstream of exon 2, which is conserved in humans and several other species but not mice. To test its function, we generated knock-in mice harboring the human APA signal. Western blotting, cell fractionation, and fluorescence microscopy were used to characterize the resulting truncated protein isoform that localizes to mitochondria. Mitochondrial functions and metabolites were assessed in neonatal rat cardiomyocytes, human-induced pluripotent stem cell–derived cardiomyocytes, and mouse hearts overexpressing the novel isoform. RESULTS: We identified a well-conserved APA signal downstream of SCN5A exon 2, yielding a truncated transcript isoform ( SCN5A -short). Reanalysis of cardiac APA-seq and mRNA-seq data reveals reduced SCN5A -short expression in failing human hearts. Knock-in of the human APA signal into mice enables expression of SCN5A -short while decreasing full-length SCN5A mRNA. SCN5A -short encodes a novel NaV1.5-NT (N-terminal fragment of NaV1.5) that localizes to the mitochondrial matrix in cardiomyocytes and mouse hearts. Exogenous expression of NaV1.5-NT in cultured cardiomyocytes enhances mitochondrial respiration, ATP production, and mitochondrial reactive oxygen species while depleting NADH (reduced nicotinamide adenine dinucleotide). Native polyacrylamide gel electrophoresis analyses indicate that this coincides with enhanced CI (complex I) activities, as well as context-dependent alterations of CV (complex V) assembly. Moreover, moderate cardiomyocyte-targeted NaV1.5-NT expression in mice was sufficient to rewire the cardiac metabolome, with suggestive evidence of increased fatty acid oxidation. CONCLUSIONS: APA-mediated regulation of SCN5A produces a short transcript encoding NaV1.5-NT, a novel mitochondrial-targeted peptide that supports cardiomyocyte metabolism. While the precise molecular mechanisms remain unresolved, these findings highlight an unforeseen alternative pathway for expanding SCN5A -mitochondrial crosstalk, with potential implications for metabolic changes in heart failure and arrhythmias.
- 9 September 2025
- Published by Wolters Kluwer Health in Circulation
- Vol. 152 (10) , 699-716
Junctophilin-2 Regulates Store-Operated Calcium Entry to Drive Cardiac Fibroblast Activation, Fibrotic Repair, and Angiogenesis After Myocardial Infarction
BACKGROUND: Calcium (Ca 2+ ) homeostasis in cardiac fibroblasts (CFs) plays a critical role in myocardial repair and remodeling after injury. JPH2 (junctophilin-2; human JPH2 or mouse Jph2) is a structural protein known to regulate intracellular Ca 2+ signaling and excitation-contraction coupling in cardiomyocytes. However, the role of JPH2 in CF biology remains unexplored. METHODS: Junctophilin expression was assayed in human and mouse CFs using reverse transcription quantitative polymerase chain reaction, Western blotting, and immunofluorescence. To investigate the functional role of Jph2 in CFs, we assessed Ca 2+ handling with live-cell confocal imaging, conducted RNA sequencing analysis, and assayed TGFβ (transforming growth factor β) responses after adenovirus-mediated gene silencing of Jph2 and fibroblast-specific Jph2 knockout. Jph2 interactions in CFs were identified using immunoprecipitation and proximity biotin ligation assays and confirmed by coimmunoprecipitation and rescue experiments. The in vivo role of Jph2 in CFs was investigated in fibroblast-specific Jph2 knockout mice (Col1a2 CreERT /Jph2 flox/flox , Jph2 fKO ) at baseline and after myocardial infarction and evaluated for changes in cardiac function, fibrosis, angiogenesis, CF activation, differentiation, and proliferation. RESULTS: Jph2 was identified as the only junctophilin expressed in CFs and acutely upregulated in response to myocardial infarction. Cellular and RNA sequencing analyses revealed that isolated Jph2-deficient CFs exhibited impaired fibroblast activation, reduced extracellular matrix production, and diminished expression of VEGFA (vascular endothelial growth factor A), VEGFB, and VEGFC after TGFβ treatment. In vivo, Jph2 fKO mice displayed exacerbated adverse cardiac remodeling after myocardial infarction, characterized by decreased CF activation/extracellular matrix production, enhanced CF proliferation, worsened systolic dysfunction, increased left ventricular dilation, impaired scar maturation, and decreased angiogenesis. Mechanistically, biochemical assays demonstrated that Jph2 interacts directly with the coiled-coil 2 domain of Stim1 (stromal interaction molecule 1) via its joining region. Jph2 knockdown led to Stim1 protein destabilization, defective store-operated Ca 2+ entry, and a reduction in both canonical and noncanonical TGFβ signaling pathways. Stim1 overexpression partially rescued the sensitivity of Jph2-deficient CFs to TGFβ, as evidenced by increased expression of periostin and fibronectin-1, as well as enhanced Smad3 phosphorylation. CONCLUSIONS: Our results demonstrate that Jph2 is required in CFs to orchestrate Ca 2+ homeostasis, CF activation, and extracellular matrix production and promotes angiogenesis in the infarcted heart, positioning it as a central regulator of cardiac repair after injury.
- 9 September 2025
- Published by Wolters Kluwer Health in Circulation
- Vol. 152 (10) , 699-716
Junctophilin-2 Regulates Store-Operated Calcium Entry to Drive Cardiac Fibroblast Activation, Fibrotic Repair, and Angiogenesis After Myocardial Infarction
BACKGROUND: Calcium (Ca 2+ ) homeostasis in cardiac fibroblasts (CFs) plays a critical role in myocardial repair and remodeling after injury. JPH2 (junctophilin-2; human JPH2 or mouse Jph2) is a structural protein known to regulate intracellular Ca 2+ signaling and excitation-contraction coupling in cardiomyocytes. However, the role of JPH2 in CF biology remains unexplored. METHODS: Junctophilin expression was assayed in human and mouse CFs using reverse transcription quantitative polymerase chain reaction, Western blotting, and immunofluorescence. To investigate the functional role of Jph2 in CFs, we assessed Ca 2+ handling with live-cell confocal imaging, conducted RNA sequencing analysis, and assayed TGFβ (transforming growth factor β) responses after adenovirus-mediated gene silencing of Jph2 and fibroblast-specific Jph2 knockout. Jph2 interactions in CFs were identified using immunoprecipitation and proximity biotin ligation assays and confirmed by coimmunoprecipitation and rescue experiments. The in vivo role of Jph2 in CFs was investigated in fibroblast-specific Jph2 knockout mice (Col1a2 CreERT /Jph2 flox/flox , Jph2 fKO ) at baseline and after myocardial infarction and evaluated for changes in cardiac function, fibrosis, angiogenesis, CF activation, differentiation, and proliferation. RESULTS: Jph2 was identified as the only junctophilin expressed in CFs and acutely upregulated in response to myocardial infarction. Cellular and RNA sequencing analyses revealed that isolated Jph2-deficient CFs exhibited impaired fibroblast activation, reduced extracellular matrix production, and diminished expression of VEGFA (vascular endothelial growth factor A), VEGFB, and VEGFC after TGFβ treatment. In vivo, Jph2 fKO mice displayed exacerbated adverse cardiac remodeling after myocardial infarction, characterized by decreased CF activation/extracellular matrix production, enhanced CF proliferation, worsened systolic dysfunction, increased left ventricular dilation, impaired scar maturation, and decreased angiogenesis. Mechanistically, biochemical assays demonstrated that Jph2 interacts directly with the coiled-coil 2 domain of Stim1 (stromal interaction molecule 1) via its joining region. Jph2 knockdown led to Stim1 protein destabilization, defective store-operated Ca 2+ entry, and a reduction in both canonical and noncanonical TGFβ signaling pathways. Stim1 overexpression partially rescued the sensitivity of Jph2-deficient CFs to TGFβ, as evidenced by increased expression of periostin and fibronectin-1, as well as enhanced Smad3 phosphorylation. CONCLUSIONS: Our results demonstrate that Jph2 is required in CFs to orchestrate Ca 2+ homeostasis, CF activation, and extracellular matrix production and promotes angiogenesis in the infarcted heart, positioning it as a central regulator of cardiac repair after injury.
- 3 August 2023
- Published by Elsevier in Heart Rhythm
- Vol. 20 (11) , 1548-1557
SUMOylation of the cardiac sodium channel NaV1.5 modifies inward current and cardiac excitability
- 3 August 2023
- Published by Elsevier in Heart Rhythm
- Vol. 20 (11) , 1548-1557
SUMOylation of the cardiac sodium channel NaV1.5 modifies inward current and cardiac excitability
- Open Access
SUMOylation of the Cardiac Sodium Channel Na V 1.5 Modifies Inward Current and Cardiac Excitability
Background: Decreased peak sodium current (I Na ) and increased late sodium current (I Na,L ), through the cardiac sodium channel Na V 1.5 encoded by SCN5A , cause arrhythmias. Many Na V 1.5 post-translational modifications have been reported by us and others. A recent report concluded that acute hypoxia increases I Na,L by increasing a Small Ubiquitin-like MOdifier (SUMOylation) at K442-Na V 1.5. Objective: To determine whether and by what mechanisms SUMOylation alters I Na , I Na,L and cardiac electrophysiology. Methods: SUMOylation of Na V 1.5 was detected by immunoprecipitation and immunoblotting. I Na was measured by patch clamp with/without SUMO1 overexpression in HEK293 cells expressing wild type (WT) or K442R-Na V 1.5 and in neonatal rat cardiac myocytes (NRCMs). SUMOylation effects were studied in vivo by electrocardiograms and ambulatory telemetry using Scn5a heterozygous knockout (SCN5A +/- ) mice and the de-SUMOylating protein SENP2 (AAV9-SENP2) or the SUMOylation inhibitor anacardic acid. Na V 1.5 trafficking was detected by immunofluorescence. Results: Na V 1.5 was SUMOylated in HEK293 cells, NRCMs and human heart tissue. HyperSUMOylation at Na V 1.5-K442 increased I Na in NRCMs and in HEK cells overexpressing WT but not K442R-Na v 1.5. SUMOylation did not alter other channel properties including I Na,L . AAV9-SENP2 or anacardic acid treatment of SCN5A +/- mice decreased I Na , prolonged QRS duration, and produced heart block and ventricular arrhythmias. SUMO1 overexpression enhanced membrane localization of Na V 1.5. Conclusion: SUMOylation of K442-Na v 1.5 increases peak I Na without changing I Na,L , at least in part by altering membrane abundance. Our findings do not support SUMOylation as a mechanism for changes in I Na,L . Na v 1.5 SUMOylation may modify arrhythmic risk in disease states and represents a potential target for pharmacological manipulation.
Open AccessSUMOylation of the Cardiac Sodium Channel Na V 1.5 Modifies Inward Current and Cardiac Excitability
Background: Decreased peak sodium current (I Na ) and increased late sodium current (I Na,L ), through the cardiac sodium channel Na V 1.5 encoded by SCN5A , cause arrhythmias. Many Na V 1.5 post-translational modifications have been reported by us and others. A recent report concluded that acute hypoxia increases I Na,L by increasing a Small Ubiquitin-like MOdifier (SUMOylation) at K442-Na V 1.5. Objective: To determine whether and by what mechanisms SUMOylation alters I Na , I Na,L and cardiac electrophysiology. Methods: SUMOylation of Na V 1.5 was detected by immunoprecipitation and immunoblotting. I Na was measured by patch clamp with/without SUMO1 overexpression in HEK293 cells expressing wild type (WT) or K442R-Na V 1.5 and in neonatal rat cardiac myocytes (NRCMs). SUMOylation effects were studied in vivo by electrocardiograms and ambulatory telemetry using Scn5a heterozygous knockout (SCN5A +/- ) mice and the de-SUMOylating protein SENP2 (AAV9-SENP2) or the SUMOylation inhibitor anacardic acid. Na V 1.5 trafficking was detected by immunofluorescence. Results: Na V 1.5 was SUMOylated in HEK293 cells, NRCMs and human heart tissue. HyperSUMOylation at Na V 1.5-K442 increased I Na in NRCMs and in HEK cells overexpressing WT but not K442R-Na v 1.5. SUMOylation did not alter other channel properties including I Na,L . AAV9-SENP2 or anacardic acid treatment of SCN5A +/- mice decreased I Na , prolonged QRS duration, and produced heart block and ventricular arrhythmias. SUMO1 overexpression enhanced membrane localization of Na V 1.5. Conclusion: SUMOylation of K442-Na v 1.5 increases peak I Na without changing I Na,L , at least in part by altering membrane abundance. Our findings do not support SUMOylation as a mechanism for changes in I Na,L . Na v 1.5 SUMOylation may modify arrhythmic risk in disease states and represents a potential target for pharmacological manipulation.
- Open Access
- 11 November 2022
- Published by Springer Nature in Cellular and Molecular Neurobiology
- Vol. 43 (5) , 2257-2271
Involvement of Ca2+ in Signaling Mechanisms Mediating Muscarinic Inhibition of M Currents in Sympathetic Neurons
Acetylcholine can excite neurons by suppressing M-type (KCNQ) potassium channels. This effect is mediated by M1muscarinic receptors coupled to the Gqprotein. Although PIP2depletion and PKC activation have been strongly suggested to contribute to muscarinic inhibition of M currents (IM), direct evidence is lacking. We investigated the mechanism involved in muscarinic inhibition of IMwith Ca2+measurement and electrophysiological studies in both neuronal (rat sympathetic neurons) and heterologous (HEK cells expressing KCNQ2/KCNQ3) preparations. We found that muscarinic inhibition of IMwas not blocked either by PIP2or by calphostin C, a PKC inhibitor. We then examined whether muscarinic inhibition of IMuses multiple signaling pathways by blocking both PIP2depletion and PKC activation. This maneuver, however, did not block muscarinic inhibition of IM. Additionally, muscarinic inhibition of IMwas not prevented either by sequestering of G-protein βγ subunits from Gα-transducin or anti-Gβγantibody or by preventing intracellular trafficking of channel proteins with blebbistatin, a class-II myosin inhibitor. Finally, we re-examined the role of Ca2+signals in muscarinic inhibition of IM. Ca2+measurements showed that muscarinic stimulation increased intracellular Ca2+and was comparable to the Ca2+mobilizing effect of bradykinin. Accordingly, 20-mM of BAPTA significantly suppressed muscarinic inhibition of IM. In contrast, muscarinic inhibition of IMwas completely insensitive to 20-mM EGTA. Taken together, these data suggest a role of Ca2+signaling in muscarinic modulation of IM. The differential effects of EGTA and BAPTA imply that Ca2+microdomains or spatially local Ca2+signals contribute to inhibition of IM.
- 11 November 2022
- Published by Springer Nature in Cellular and Molecular Neurobiology
- Vol. 43 (5) , 2257-2271
Open AccessInvolvement of Ca2+ in Signaling Mechanisms Mediating Muscarinic Inhibition of M Currents in Sympathetic Neurons
Acetylcholine can excite neurons by suppressing M-type (KCNQ) potassium channels. This effect is mediated by M1muscarinic receptors coupled to the Gqprotein. Although PIP2depletion and PKC activation have been strongly suggested to contribute to muscarinic inhibition of M currents (IM), direct evidence is lacking. We investigated the mechanism involved in muscarinic inhibition of IMwith Ca2+measurement and electrophysiological studies in both neuronal (rat sympathetic neurons) and heterologous (HEK cells expressing KCNQ2/KCNQ3) preparations. We found that muscarinic inhibition of IMwas not blocked either by PIP2or by calphostin C, a PKC inhibitor. We then examined whether muscarinic inhibition of IMuses multiple signaling pathways by blocking both PIP2depletion and PKC activation. This maneuver, however, did not block muscarinic inhibition of IM. Additionally, muscarinic inhibition of IMwas not prevented either by sequestering of G-protein βγ subunits from Gα-transducin or anti-Gβγantibody or by preventing intracellular trafficking of channel proteins with blebbistatin, a class-II myosin inhibitor. Finally, we re-examined the role of Ca2+signals in muscarinic inhibition of IM. Ca2+measurements showed that muscarinic stimulation increased intracellular Ca2+and was comparable to the Ca2+mobilizing effect of bradykinin. Accordingly, 20-mM of BAPTA significantly suppressed muscarinic inhibition of IM. In contrast, muscarinic inhibition of IMwas completely insensitive to 20-mM EGTA. Taken together, these data suggest a role of Ca2+signaling in muscarinic modulation of IM. The differential effects of EGTA and BAPTA imply that Ca2+microdomains or spatially local Ca2+signals contribute to inhibition of IM.
- Open Access
- 25 July 2022
- Published by Wiley in Clinical and Translational Medicine
- Vol. 12 (7) , e954
Metabolic rescue ameliorates mitochondrial encephalo‐cardiomyopathy in murine and human iPSC models of Leigh syndrome
Background: Mice with deletion of complex I subunit Ndufs4 develop mitochondrial encephalomyopathy resembling Leigh syndrome (LS). The metabolic derangement and underlying mechanisms of cardio‐encephalomyopathy in LS remains incompletely understood.Methods: We performed echocardiography, electrophysiology, confocal microscopy, metabolic and molecular/morphometric analysis of the mice lacking Ndufs4. HEK293 cells, human iPS cells‐derived cardiomyocytes and neurons were used to determine the mechanistic role of mitochondrial complex I deficiency.Results: LS mice develop severe cardiac bradyarrhythmia and diastolic dysfunction. Human‐induced pluripotent stem cell‐derived cardiomyocytes (iPS‐CMs) with Ndufs4 deletion recapitulate LS cardiomyopathy. Mechanistically, we demonstrate a direct link between complex I deficiency, decreased intracellular (nicotinamide adenine dinucleotide) NAD+/NADH and bradyarrhythmia, mediated by hyperacetylation of the cardiac sodium channel NaV1.5, particularly at K1479 site. Neuronal apoptosis in the cerebellar and midbrain regions in LS mice was associated with hyperacetylation of p53 and activation of microglia. Targeted metabolomics revealed increases in several amino acids and citric acid cycle intermediates, likely due to impairment of NAD+‐dependent dehydrogenases, and a substantial decrease in reduced Glutathione (GSH). Metabolic rescue by nicotinamide riboside (NR) supplementation increased intracellular NAD+/ NADH, restored metabolic derangement, reversed protein hyperacetylation through NAD+‐dependent Sirtuin deacetylase, and ameliorated cardiomyopathic phenotypes, concomitant with improvement of NaV1.5 current and SERCA2a function measured by Ca2+‐transients. NR also attenuated neuronal apoptosis and microglial activation in the LS brain and human iPS‐derived neurons with Ndufs4 deletion.Conclusions: Our study reveals direct mechanistic explanations of the observed cardiac bradyarrhythmia, diastolic dysfunction and neuronal apoptosis in mouse and human induced pluripotent stem cells (iPSC) models of LS.
- 25 July 2022
- Published by Wiley in Clinical and Translational Medicine
- Vol. 12 (7) , e954
Open AccessMetabolic rescue ameliorates mitochondrial encephalo‐cardiomyopathy in murine and human iPSC models of Leigh syndrome
Background: Mice with deletion of complex I subunit Ndufs4 develop mitochondrial encephalomyopathy resembling Leigh syndrome (LS). The metabolic derangement and underlying mechanisms of cardio‐encephalomyopathy in LS remains incompletely understood.Methods: We performed echocardiography, electrophysiology, confocal microscopy, metabolic and molecular/morphometric analysis of the mice lacking Ndufs4. HEK293 cells, human iPS cells‐derived cardiomyocytes and neurons were used to determine the mechanistic role of mitochondrial complex I deficiency.Results: LS mice develop severe cardiac bradyarrhythmia and diastolic dysfunction. Human‐induced pluripotent stem cell‐derived cardiomyocytes (iPS‐CMs) with Ndufs4 deletion recapitulate LS cardiomyopathy. Mechanistically, we demonstrate a direct link between complex I deficiency, decreased intracellular (nicotinamide adenine dinucleotide) NAD+/NADH and bradyarrhythmia, mediated by hyperacetylation of the cardiac sodium channel NaV1.5, particularly at K1479 site. Neuronal apoptosis in the cerebellar and midbrain regions in LS mice was associated with hyperacetylation of p53 and activation of microglia. Targeted metabolomics revealed increases in several amino acids and citric acid cycle intermediates, likely due to impairment of NAD+‐dependent dehydrogenases, and a substantial decrease in reduced Glutathione (GSH). Metabolic rescue by nicotinamide riboside (NR) supplementation increased intracellular NAD+/ NADH, restored metabolic derangement, reversed protein hyperacetylation through NAD+‐dependent Sirtuin deacetylase, and ameliorated cardiomyopathic phenotypes, concomitant with improvement of NaV1.5 current and SERCA2a function measured by Ca2+‐transients. NR also attenuated neuronal apoptosis and microglial activation in the LS brain and human iPS‐derived neurons with Ndufs4 deletion.Conclusions: Our study reveals direct mechanistic explanations of the observed cardiac bradyarrhythmia, diastolic dysfunction and neuronal apoptosis in mouse and human induced pluripotent stem cells (iPSC) models of LS.
- Open Access
Modulation of the Cardiac Sodium Channel Na V 1.5 Peak and Late Currents by NAD + Precursors
Rationale: The cardiac sodium channel Na V 1.5, encoded by SCN5A , produces the rapidly inactivating depolarizing current I Na that is responsible for the initiation and propagation of the cardiac action potential. Acquired and inherited dysfunction of Na V 1.5 results in either decreased peak I Na or increased residual late I Na (I Na,L ), leading to tachy/bradyarrhythmias and sudden cardiac death. Previous studies have shown that increased cellular NAD + and NAD + /NADH ratio increase I Na through suppression of mitochondrial reactive oxygen species and PKC-mediated Na V 1.5 phosphorylation. In addition, NAD + -dependent deacetylation of Na V 1.5 at K1479 by Sirtuin 1 increases Na V 1.5 membrane trafficking and I Na . The role of NAD + precursors in modulating I Na remains unknown. Objective: To determine whether and by which mechanisms the NAD + precursors nicotinamide riboside (NR) and nicotinamide (NAM) affect peak I Na and I Na,L in vitro and cardiac electrophysiology in vivo . Methods and Results: The effects of NAD + precursors on the NAD + metabolome and electrophysiology were studied using HEK293 cells expressing wild-type and mutant Na V 1.5, rat neonatal cardiomyocytes (RNCMs), and mice. NR increased I Na in HEK293 cells expressing Na V 1.5 (500 μM: 51 ± 18%, p=0.02, 5 mM: 59 ± 22%, p=0.03) and RNCMs (500 µM: 60 ± 26%, p=0.02, 5 mM: 75 ± 39%, p=0.03) while reducing I Na,L at the higher concentration (RNCMs, 5 mM: −45 ± 11%, p=0.04). NR (5 mM) decreased Na V 1.5 K1479 acetylation but increased I Na in HEK293 cells expressing a mutant form of Na V 1.5 with disruption of the acetylation site (Na V 1.5-K1479A). Disruption of the PKC phosphorylation site abolished the effect of NR on I Na . Furthermore, NAM (5 mM) had no effect on I Na in RNCMs or in HEK293 cells expressing wild-type Na V 1.5, but increased I Na in HEK293 cells expressing Na V 1.5-K1479A. Dietary supplementation with NR for 10-12 weeks decreased QTc in C57BL/6J mice (0.35% NR: −4.9 ± 2.0%, p=0.26; 1.0% NR: −9.5 ± 2.8%, p=0.01). Conclusions: NAD + precursors differentially regulate Na V 1.5 via multiple mechanisms. NR increases I Na , decreases I Na,L , and warrants further investigation as a potential therapy for arrhythmic disorders caused by Na V 1.5 deficiency and/or dysfunction.
Open AccessModulation of the Cardiac Sodium Channel Na V 1.5 Peak and Late Currents by NAD + Precursors
Rationale: The cardiac sodium channel Na V 1.5, encoded by SCN5A , produces the rapidly inactivating depolarizing current I Na that is responsible for the initiation and propagation of the cardiac action potential. Acquired and inherited dysfunction of Na V 1.5 results in either decreased peak I Na or increased residual late I Na (I Na,L ), leading to tachy/bradyarrhythmias and sudden cardiac death. Previous studies have shown that increased cellular NAD + and NAD + /NADH ratio increase I Na through suppression of mitochondrial reactive oxygen species and PKC-mediated Na V 1.5 phosphorylation. In addition, NAD + -dependent deacetylation of Na V 1.5 at K1479 by Sirtuin 1 increases Na V 1.5 membrane trafficking and I Na . The role of NAD + precursors in modulating I Na remains unknown. Objective: To determine whether and by which mechanisms the NAD + precursors nicotinamide riboside (NR) and nicotinamide (NAM) affect peak I Na and I Na,L in vitro and cardiac electrophysiology in vivo . Methods and Results: The effects of NAD + precursors on the NAD + metabolome and electrophysiology were studied using HEK293 cells expressing wild-type and mutant Na V 1.5, rat neonatal cardiomyocytes (RNCMs), and mice. NR increased I Na in HEK293 cells expressing Na V 1.5 (500 μM: 51 ± 18%, p=0.02, 5 mM: 59 ± 22%, p=0.03) and RNCMs (500 µM: 60 ± 26%, p=0.02, 5 mM: 75 ± 39%, p=0.03) while reducing I Na,L at the higher concentration (RNCMs, 5 mM: −45 ± 11%, p=0.04). NR (5 mM) decreased Na V 1.5 K1479 acetylation but increased I Na in HEK293 cells expressing a mutant form of Na V 1.5 with disruption of the acetylation site (Na V 1.5-K1479A). Disruption of the PKC phosphorylation site abolished the effect of NR on I Na . Furthermore, NAM (5 mM) had no effect on I Na in RNCMs or in HEK293 cells expressing wild-type Na V 1.5, but increased I Na in HEK293 cells expressing Na V 1.5-K1479A. Dietary supplementation with NR for 10-12 weeks decreased QTc in C57BL/6J mice (0.35% NR: −4.9 ± 2.0%, p=0.26; 1.0% NR: −9.5 ± 2.8%, p=0.01). Conclusions: NAD + precursors differentially regulate Na V 1.5 via multiple mechanisms. NR increases I Na , decreases I Na,L , and warrants further investigation as a potential therapy for arrhythmic disorders caused by Na V 1.5 deficiency and/or dysfunction.
- 16 May 2019
- Published by IOP Publishing in Biomedical Physics & Engineering Express
- Vol. 5 (4) , 045003
Magnetic resonance imaging of contracting ultrathin cardiac tissue
Objective : Integrating cardiac-tissue patches into the beating heart and evaluating the long-term effects of such integration on cardiac contractility are two challenges in an emerging field of regenerative medicine. This pilot study presents tools for the imaging of contracting multicellular cardiac tissue constructs (MTCs) in vitro and demonstrates the feasibility of tracking the early development of strand geometry and contractions in ultrathin strands and layers of cardiac tissue using CINE MRI. Approach: Cultured, ultrathin (∼50–100-micron) MTCs of rat neonatal cardiomyocytes were plated in rectangular cell chambers (4.5 × 2.0 cm) with and without ultrathin, carbon EP electrodes embedded in the floor of the cell chamber. Two-dimensional, steady-state free precession (SSFP) CINE MRI, cell microscopy, and tissue photography were performed on Days 5–9 of cell development. Potential confounders and MRI artifacts were evaluated using non-contracting cardiac tissues and cell-free chambers filled with the cell-culture medium. Main results: Synchronized contractions formed by Day 7; individual contracting tissue strands became identifiable by Day 9. The global patterns and details of the strand geometry and movement patterns in the SSFP images were in excellent agreement with microscopic and photographic images. No synchronized movement was identifiable by either microscopy or CINE MRI in the non-contracting MTCs or the cell-free medium. The EP recordings revealed well-defined depolarization and repolarization waveforms; the imaging artifacts generated by the carbon electrodes were small. Significance: This pilot study demonstrates the feasibility of imaging cardiac-strand patterns and contractile activity in ultrathin, two-dimensional cardiac tissue in commonly used clinical scanners.
- 16 May 2019
- Published by IOP Publishing in Biomedical Physics & Engineering Express
- Vol. 5 (4) , 045003
Magnetic resonance imaging of contracting ultrathin cardiac tissue
Objective : Integrating cardiac-tissue patches into the beating heart and evaluating the long-term effects of such integration on cardiac contractility are two challenges in an emerging field of regenerative medicine. This pilot study presents tools for the imaging of contracting multicellular cardiac tissue constructs (MTCs) in vitro and demonstrates the feasibility of tracking the early development of strand geometry and contractions in ultrathin strands and layers of cardiac tissue using CINE MRI. Approach: Cultured, ultrathin (∼50–100-micron) MTCs of rat neonatal cardiomyocytes were plated in rectangular cell chambers (4.5 × 2.0 cm) with and without ultrathin, carbon EP electrodes embedded in the floor of the cell chamber. Two-dimensional, steady-state free precession (SSFP) CINE MRI, cell microscopy, and tissue photography were performed on Days 5–9 of cell development. Potential confounders and MRI artifacts were evaluated using non-contracting cardiac tissues and cell-free chambers filled with the cell-culture medium. Main results: Synchronized contractions formed by Day 7; individual contracting tissue strands became identifiable by Day 9. The global patterns and details of the strand geometry and movement patterns in the SSFP images were in excellent agreement with microscopic and photographic images. No synchronized movement was identifiable by either microscopy or CINE MRI in the non-contracting MTCs or the cell-free medium. The EP recordings revealed well-defined depolarization and repolarization waveforms; the imaging artifacts generated by the carbon electrodes were small. Significance: This pilot study demonstrates the feasibility of imaging cardiac-strand patterns and contractile activity in ultrathin, two-dimensional cardiac tissue in commonly used clinical scanners.
- Open Access
- 29 January 2018
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 128 (3) , 1154-1163
A common variant alters SCN5A–miR-24 interaction and associates with heart failure mortality
SCN5A encodes the voltage-gated Na+ channel NaV1.5 that is responsible for depolarization of the cardiac action potential and rapid intercellular conduction. Mutations disrupting the SCN5A coding sequence cause inherited arrhythmias and cardiomyopathy, and single-nucleotide polymorphisms (SNPs) linked to SCN5A splicing, localization, and function associate with heart failure–related sudden cardiac death. However, the clinical relevance of SNPs that modulate SCN5A expression levels remains understudied. We recently generated a transcriptome-wide map of microRNA (miR) binding sites in human heart, evaluated their overlap with common SNPs, and identified a synonymous SNP (rs1805126) adjacent to a miR-24 site within the SCN5A coding sequence. This SNP was previously shown to reproducibly associate with cardiac electrophysiological parameters, but was not considered to be causal. Here, we show that miR-24 potently suppresses SCN5A expression and that rs1805126 modulates this regulation. We found that the rs1805126 minor allele associates with decreased cardiac SCN5A expression and that heart failure subjects homozygous for the minor allele have decreased ejection fraction and increased mortality, but not increased ventricular tachyarrhythmias. In mice, we identified a potential basis for this in discovering that decreased Scn5a expression leads to accumulation of myocardial reactive oxygen species. Together, these data reiterate the importance of considering the mechanistic significance of synonymous SNPs as they relate to miRs and disease, and highlight a surprising link between SCN5A expression and nonarrhythmic death in heart failure.
- 29 January 2018
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 128 (3) , 1154-1163
Open AccessA common variant alters SCN5A–miR-24 interaction and associates with heart failure mortality
SCN5A encodes the voltage-gated Na+ channel NaV1.5 that is responsible for depolarization of the cardiac action potential and rapid intercellular conduction. Mutations disrupting the SCN5A coding sequence cause inherited arrhythmias and cardiomyopathy, and single-nucleotide polymorphisms (SNPs) linked to SCN5A splicing, localization, and function associate with heart failure–related sudden cardiac death. However, the clinical relevance of SNPs that modulate SCN5A expression levels remains understudied. We recently generated a transcriptome-wide map of microRNA (miR) binding sites in human heart, evaluated their overlap with common SNPs, and identified a synonymous SNP (rs1805126) adjacent to a miR-24 site within the SCN5A coding sequence. This SNP was previously shown to reproducibly associate with cardiac electrophysiological parameters, but was not considered to be causal. Here, we show that miR-24 potently suppresses SCN5A expression and that rs1805126 modulates this regulation. We found that the rs1805126 minor allele associates with decreased cardiac SCN5A expression and that heart failure subjects homozygous for the minor allele have decreased ejection fraction and increased mortality, but not increased ventricular tachyarrhythmias. In mice, we identified a potential basis for this in discovering that decreased Scn5a expression leads to accumulation of myocardial reactive oxygen species. Together, these data reiterate the importance of considering the mechanistic significance of synonymous SNPs as they relate to miRs and disease, and highlight a surprising link between SCN5A expression and nonarrhythmic death in heart failure.